Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the
angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR),
Fibroblast Growth Factor Receptor(FGFR), Platelet-Derived Growth Factor Receptor(PDGFR), and
tumor cell proliferation related kinase c-Kit kinase. Anlotinib is an efficient second line
therapeutic agent in treatment for metastatic soft tissue sarcoma which has been approved in
clinical trials (ALTER-0203). There is a sort of patients who are not candidate for standard
first line chemotherapy that is doxorubicin based. The patients either refused or too old and
and debilitated to receive the cytotoxic chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Hangzhou Third Hospital Jiangsu Cancer Institute & Hospital Jiangsu Provincial People's Hospital Ningbo No.2 Hospital The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Zhejiang Cancer Hospital